Derek Holt
Psychiatric/Mental Health · Missoula, MTNPI 1972233369
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 26.3% of the total. 2025 is the largest year on record at $480, 6.5 times the $74 reported in 2023.
Across 37 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$176
- Teva Pharmaceuticals USA, Inc.$134
- Neurocrine Biosciences, Inc.$107
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$93
- Vanda Pharmaceuticals Inc.$91
- Indivior Inc.$37
- plus $33 from 2 others
What the payments were for
- Food & beverage$671100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $176 |
| Teva Pharmaceuticals USA, Inc. | 7 | $134 |
| Neurocrine Biosciences, Inc. | 5 | $107 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $93 |
| Vanda Pharmaceuticals Inc. | 3 | $91 |
| Indivior Inc. | 2 | $37 |
| Johnson & Johnson | 1 | $18 |
| Corium, LLC | 1 | $15 |
How this compares
$671 in reported general payments places this provider in the 85th percentile of 142 psychiatric/mental health providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $3,629 |
| Bupropion XlBupropion Hcl | 52 | $2,849 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 38 | $1,174 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $934 |
| Fluoxetine Hcl | 35 | $756 |
| Mirtazapine | 47 | $687 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 51 | $516 |
| Quetiapine Fumarate | 44 | $499 |
| Divalproex Sodium | 22 | $440 |
| Prazosin Hcl | 13 | $415 |
| Escitalopram Oxalate | 37 | $354 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $351 |
| Lamotrigine | 27 | $337 |
| Clonazepam | 70 | $334 |
| Trazodone Hcl | 47 | $315 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Missoula
- Sherry MartinMissoula$3K
- Michael DuchschereMissoula$852
- Mark McGrathMissoula$681
- Leigh TorcolettiMissoula$633
- Evan ThompsonMissoula$585
- Wendy FlansburgMissoula$469
- Shannon ScallyMissoula$350
- Ruth MonsonMissoula$346
- Sydney SeyfertMissoula$345
- Donna BergrenMissoula$334
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.